The short version of counter-ion fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-23 and is reviewed periodically as new material appears.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Countries requiring passports valid for at least 4 months on arrival include Micronesia and Zambia. Countries requiring passports with a validity of at least 3 months beyond the date of intended departure include Azerbaijan, Bosnia and Herzegovina, Honduras, Montenegro, Nauru, Moldova and New Zealand. Similarly, the EEA countries of Iceland, Liechtenstein, Norway, all European Union countries (except Ireland) together with Switzerland also require 3 months validity beyond the date of the bearer's intended departure unless the bearer is an EEA or Swiss national. Countries requiring passports valid for at least 3 months on arrival include Albania, North Macedonia, Panama, and Senegal. Bermuda requires passports to be valid for at least 45 days upon entry. Countries that require a passport validity of at least one month beyond the date of intended departure include Eritrea, Hong Kong, Lebanon, Macau, the Maldives and South Africa.
== Implementation == A simple representation can be made by defining two oppositely charged polyions as + and -, and defining the wash step as W. To make an LbL film with 5 bilayers one would deposit W+W-W+W-W+W-W+W-W+W-W, which would lead to a film with 5 bilayers, specifically + - + - + - + - + - . The representation of the LbL technique as a multilayer build-up based solely on electrostatic attraction is a simplification. Other interactions are involved in this process, including hydrophobic attraction. Multilayer build-up is enabled by multiple attractive forces acting cooperatively, typical for high-molecular weight building blocks, while electrostatic repulsion provides self-limitation of the absorption of individual layers. This range of interactions makes it possible to extend the LbL technique to hydrogen-bonded films, nanoparticles, similarly charged polymers, hydrophobic solvents, and other unusual systems. The bilayers and wash steps can be performed in many different ways including dip coating, spin-coating, spray-coating, flow based techniques and electro-magnetic techniques. The preparation method distinctly impacts the properties of the resultant films, allowing various applications to be realized. For example, a whole car has been coated with spray assembly, optically transparent films have been prepared with spin assembly, etc. Characterization of LbL film deposition is typically done by optical techniques such as dual polarisation interferometry or ellipsometry or mechanical techniques such as quartz crystal microbalance.
== Honors received == American Chemical Society Award in Separations Science and Technology, 2021 Special issue of the "Journal of Chromatography A" honoring James Jorgenson, November 2017 Lifetime Achievement Award, LCGC Magazine North America, 2011 American Chemical Society Award in Analytical Chemistry, 2007 Elected Member of the American Academy of Arts and Sciences, 2007 Lifetime Achievement Award, LCGC Magazine Europe, 2006 Special issue of the journal "Electrophoresis" dedicated to J. W. Jorgenson, October 2001 American Chemical Society Award in Chromatography, 1993
Narrated by Stephen Rashbrook, produced by Nick Catliff, directed by Henry Singer, made by Lion Television and Sandpaper Films. Shown on Monday 7 February 2000 on The Nature of Things in Canada 27 September Near Miss, about ATC, the 1960 New York mid-air collision in December 1960; around 7,500 aircraft visit the three airports each day; LaGuardia Airport has two conjoined runways that operate in a strange mixed way; on 3 April 1998 there was a near miss; USAir Flight 5050 in September 1989; Colombian Avianca Flight 52 in January 1990 approached John F. Kennedy International Airport when running out of fuel, when a 4-hour flight turned into 6 hours due to weather. Narrated by Jack Davenport, directed by Jeremy Llewellyn-Jones, produced by Emma Bowman, made by Windfall Films and The Learning Channel (TLC). On All 4 4 October Curing the Incurable, the strange teratoma cells; Paul R. Sanberg of the University of South Florida; Irving Weissman of Stanford University; pathologist John Goepel; Peter Andrews (biologist); neurosurgeon Douglas Kondziolka of the University of Pittsburgh Medical Center, and stereotactic surgery; John Sinden of ReNeuron; Ann Tsukamoto of CytoTherapeutics. Narrated by David Malone, made by Boa Picture Company 20 December Talking with Aliens, an Equinox Special, with zoologist Denise L. Herzing, made by Pioneer Films
Experiments using iTRAQ labeling and LC-MS/MS with STEP and PSP peptide internal standards have successfully quantified total and active protease levels in biological samples. One major drawback for this approach is the inability to account for inhibitor bound enzymes. It is also difficult to ensure standard peptides can be generated for this method for each and every protease for study. However, PSPs hold large potential for translating degradomics into clinical applications, as once a PSP is established it could aid in quantifying proteolytic signature biomarkers in Single Reaction Monitoring (SRM) and Multiple Reaction Monitoring (MRM) type clinical assays.
Sources: en.wikipedia.org
Cold fusion is a hypothesized type of nuclear reaction that would occur at, or near, room temperature. It would contrast starkly with the "hot" fusion that is known to take place naturally within stars, artificially in hydrogen bombs, and within prototype fusion reactors; all of which occur at temperatures of millions of degrees. It is also distinguished from muon-catalyzed fusion. There is currently no accepted theoretical model that describes how cold fusion could occur. In 1989, two electrochemists at the University of Utah, Martin Fleischmann and Stanley Pons, reported that their apparatus containing heavy water had produced anomalous heat ("excess heat") of a magnitude they asserted would defy explanation except in terms of nuclear processes. They further reported measuring small amounts of nuclear reaction byproducts, including neutrons and tritium, both of which are produced by fusion of deuterium, found in heavy water (see Fusion power § Deuterium). The small tabletop experiment involved electrolysis of heavy water on the surface of a palladium (Pd) electrode. The reported results received wide media attention and raised hopes of a cheap and abundant source of energy. Both neutrons and tritium are found in trace amounts from natural sources. These traces are produced by cosmic ray interactions and nuclear radioactive decays occurring in the atmosphere and the earth. Many scientists tried to replicate the experiment with the few details available.
=== The Human Chimera Prohibition Act === On 11 July 2005, a bill known as The Human Chimera Prohibition Act was introduced into the United States Congress by Senator Samuel Brownback; however, it died in Congress sometime in the next year. The bill was introduced based on findings that science had progressed to the point where human and nonhuman species could be merged to create new forms of life. Because of this, ethical issues might arise as the line blurred between humans and other animals, and according to the bill with this blurring of lines would come a show of disrespect for human dignity. The final claim brought up in The Human Chimera Prohibition Act was that there was an increasing amount of zoonotic diseases, and that the creation of human-animal chimeras might allow these diseases to reach humans. On 22 August 2016, another bill, The Human-Animal Chimera Prohibition Act of 2016, was introduced to the United States House of Representatives by Christopher H. Smith. It identified a human-animal chimera as:
== Projects == Oncocheck ONCOCHECK is a set of clinical studies conducted by Life Length during 2017. The aim of the project was the clinical validation of telomere-associated variables (TAVs) as cancer biomarkers. It involved more than 1,200 adults and 300 children suffering from one of multiple existing types of cancer, including breast, prostate, lung, and leukemia cancers, among others. ONCOCHECK received funding from the European Union's Horizon 2020 research and innovation program. With more than 7,000 peer-reviewed scientific and clinical publications, telomere length measurement has established itself as a biomarker in cancer diagnosis and prognosis. This project has the invaluable support of some of the most important hospitals in Spain such as "University Hospital 12 de octubre", "University Hospital Puerta de Hierro", "University Hospital Niño Jesús", "Vall d'Hebron Hospital", and "Centro Integral Oncológico Clara Campal (CIOCC)". Within the ONCOCHECK project, Life Length is also conducting studies in advanced solid tumors and chronic lymphocytic leukemia (CLL). The results of the ONCOCHECK project have enabled Life Length to develop new applications in oncology . Prostate cancer diagnosis product Telomeres as cancer biomarkers: Tumor cells work differently from normal cells. As a cell becomes cancerous, it divides more frequently, and its telomeres shorten faster. Cancer cells avoid senescence/death and instead become immortal with the ability to replicate indefinitely, even when telomeres are short.
=== Research Award (since 1986) === 2025 Tian (Autumn) Qiu 2024 Elizabeth K. Neumann 2023 Kelly Marie Hines and Stacy Malaker 2022 Gloria Sheynkman 2021 Xin Yan 2019 Eleanor Browne 2014 Kerri A. Pratt 2013 Yu Xia 2012 Ileana M. Cristea and Sharon J. Pitteri 2011 Judit Villen 2010 Sarah Trimpin 2007 Rebecca Jockusch 2006 Heather Desaire 2005 Kristina Hăkansson 2004 Lingjun Li 2003 Andrea Grottoli 2001 Deborah S. Gross 2000 Elaine Marzluff 1998 Mary T. Rodgers 1997 M. Judith Charles 1994 Kimberly A. Prather 1993 Susan Graul 1992 Vicki H. Wysocki 1991 Hilkka I. Kenttämaa 1990 Jennifer Brodbelt 1987 Susan Olesik
== History == Fremanezumab was discovered and developed by Rinat Neuroscience, was acquired by Pfizer in 2006, and was then licensed to Teva. It was approved by the US Food and Drug Administration in September 2018. In March 2019, fremanezumab was approved for marketing and use in the European Union.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.